Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617

ClinicalTrials.gov ID: NCT06785636

Public ClinicalTrials.gov record NCT06785636. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 6, 2026, 8:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b/2a, MultiCenter, Open- Label Study of Pocenbrodib as Monotherapy or in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Study identification

NCT ID: NCT06785636
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Pathos AI, Inc.; Industry
Enrollment: 252 participants

Conditions and interventions

Conditions

Interventions

Cohort 2A (Pocenbrodib monotherapy), Cohort 2B (Pocenbrodib + abiraterone acetate), Cohort 2C (Pocenbrodib + olaparib), Cohort 2D (Pocenbrodib + 177Lu-PSMA-617 Drug
Pocenbrodib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 6, 2025
Primary completion: Jun 29, 2028
Completion: Apr 29, 2029
Last update posted: Apr 23, 2026

2025 – 2029

United States locations

U.S. sites: 18
U.S. states: 15
U.S. cities: 18

Facility	City	State	ZIP	Site status
MemorialCare Orange Coast Medical Center	Fountain Valley	California	92708	Recruiting
Cancer and Blood Research Center	Los Alamitos	California	90720	Recruiting
University of Colorado Health	Aurora	Colorado	80045	Recruiting
Mount Sinai Medical Center	Miami	Florida	33140	Recruiting
Emory University Hospital	Atlanta	Georgia	30322	Recruiting
University of Chicago	Chicago	Illinois	60637	Recruiting
Community Health Network	Indianapolis	Indiana	46250	Recruiting
Ochsner	Jefferson	Louisiana	70121	Recruiting
Johns Hopkins Hospital	Baltimore	Maryland	21287	Recruiting
Karmanos Cancer Institute	Detroit	Michigan	48201	Recruiting
Siteman Cancer Center	St Louis	Missouri	63108	Recruiting
Nebraska Cancer Specialists	Omaha	Nebraska	68130	Recruiting
Duke University medical center	Durham	North Carolina	27710	Recruiting
The Ohio State University	Columbus	Ohio	43210	Recruiting
Taylor Cancer Research Center	Maumee	Ohio	43537	Recruiting
University of Texas Southwestern Medical Center	Dallas	Texas	75390	Recruiting
Oncology Consultants, P.A	Houston	Texas	77030	Recruiting
NEXT Oncology - Virginia	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06785636, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 23, 2026 · Synced May 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06785636 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →